Samuli Ripatti - Selected Publications#

Publications: Google Scholar: 303 articles; Citations 72191; 38 papers with >500 citations; h-index 111

Full publication list

1. A catalog of genetic predictors impacting lifelong medication use patterns in hyperlipidemia, hypertension and type 2 diabetes. Tuomo Kiiskinen, Pyry Helkkula, Kristi Krebs, Juha Karjalainen, Elmo Saarentaus, Nina Mars, Arto Lehisto, Wei Zhou, Mattia Cordioli, Sakari Jukarainen, Joel T. Rämö, Juha Mehtonen, Kumar Veerapen, Markus Räsänen, Sanni Ruotsalainen, Mutaamba Maasha, FinnGen, Teemu Niiranen, Tiinamaija Tuomi, Veikko Salomaa, Mitja Kurki, Matti Pirinen, Aarno Palotie, Mark Daly, Andrea Ganna, Aki S. Havulinna, Lili Milani, Samuli Ripatti. Nature Medicine, 2023 Jan;29(1):209-218. doi: 10.1038/s41591-022-02122-5.

2. Genome-wide risk prediction of common diseases across ancestries in one million people. Mars N, Kerminen S, Feng YA, Kanai M, Läll K, Thomas LF, Skogholt AH, Della Briotta Parolo P; Biobank Japan Project; FinnGen, Neale BM, Smoller JW, Gabrielsen ME, Hveem K, Mägi R, Matsuda K, Okada Y, Pirinen M, Palotie A, Ganna A, Martin AR, Ripatti S. Cell Genomics. 2022 Apr 13;2(4):None. doi: 10.1016/j.xgen.2022.100118.PMID: 35591975

3. How Communicating Polygenic and Clinical Risk for Atherosclerotic Cardiovascular Disease Impacts Health Behavior: an Observational Follow-up Study. Widén E, Junna N, Ruotsalainen S, Surakka I, Mars N, Ripatti P, Partanen JJ, Aro J, Mustonen P, Tuomi T, Palotie A, Salomaa V, Kaprio J, Partanen J, Hotakainen K, Pöllänen P, Ripatti S. Circ Genom Precis Med. 2022 Apr;15(2):e003459. doi: 10.1161/CIRCGEN.121.003459. Epub 2022 Feb 7.PMID: 35130028

4. Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps. Polygenic Risk Score Task Force of the International Common Disease Alliance. Nature Medicine 2021 Nov;27(11):1876-1884. doi: 10.1038/s41591-021-01549-6.

5. Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers. Mars N, Koskela JT, Ripatti P, Kiiskinen TTJ, Havulinna AS, Lindbohm JV, Ahola-Olli A, Kurki M, Karjalainen J, Palta P; FinnGen, Neale BM, Daly M, Salomaa V, Palotie A, Widén E, Ripatti S. Nature Medicine. 2020 Apr;26(4):549-557. doi: 10.1038/s41591-020-0800-0. Epub 2020 Apr 7.PMID: 32273609

6. Genetic architecture of human plasma lipidome and its link to cardiovascular disease. Tabassum R, Rämö JT, Ripatti P, Koskela JT, Kurki M, Karjalainen J, Palta P, Hassan S, Nunez-Fontarnau J, Kiiskinen TTJ, Söderlund S, Matikainen N, Gerl MJ, Surma MA, Klose C, Stitziel NO, Laivuori H, Havulinna AS, Service SK, Salomaa V, Pirinen M; FinnGen Project, Jauhiainen M, Daly MJ, Freimer NB, Palotie A, Taskinen MR, Simons K, Ripatti S. Nature Communications. 2019 Sep 24;10(1):4329. doi: 10.1038/s41467-019-11954-8.PMID: 31551469

7. Exome sequencing of Finnish isolates enhances rare-variant association power. Locke AE, Steinberg KM, Chiang CWK, Service SK, Havulinna AS, Stell L, Pirinen M, Abel HJ, Chiang CC, Fulton RS, Jackson AU, Kang CJ, Kanchi KL, Koboldt DC, Larson DE, Nelson J, Nicholas TJ, Pietilä A, Ramensky V, Ray D, Scott LJ, Stringham HM, Vangipurapu J, Welch R, Yajnik P, Yin X, Eriksson JG, Ala-Korpela M, Järvelin MR, Männikkö M, Laivuori H; FinnGen Project, Dutcher SK, Stitziel NO, Wilson RK, Hall IM, Sabatti C, Palotie A, Salomaa V, Laakso M, Ripatti S, Boehnke M, Freimer NB. Nature. 2019 Aug;572(7769):323-328. doi: 10.1038/s41586-019-1457-z. Epub 2019 Jul 31.PMID: 31367044

8. The impact of low-frequency and rare variants on lipid levels. Surakka I, Horikoshi M, Mägi R, Sarin AP, Mahajan A, Lagou V, Marullo L, Ferreira T, Miraglio B, Timonen S, Kettunen J, Pirinen M, Karjalainen J, Thorleifsson G, Hägg S, Hottenga JJ, Isaacs A, Ladenvall C, Beekman M, Esko T, Ried JS, Nelson CP, Willenborg C, Gustafsson S, Westra HJ, Blades M, de Craen AJ, de Geus EJ, Deelen J, Grallert H, Hamsten A, Havulinna AS, Hengstenberg C, Houwing-Duistermaat JJ, Hyppönen E, Karssen LC, Lehtimäki T, Lyssenko V, Magnusson PK, Mihailov E, Müller-Nurasyid M, Mpindi JP, Pedersen NL, Penninx BW, Perola M, Pers TH, Peters A, Rung J, Smit JH, Steinthorsdottir V, Tobin MD, Tsernikova N, van Leeuwen EM, Viikari JS, Willems SM, Willemsen G, Schunkert H, Erdmann J, Samani NJ, Kaprio J, Lind L, Gieger C, Metspalu A, Slagboom PE, Groop L, van Duijn CM, Eriksson JG, Jula A, Salomaa V, Boomsma DI, Power C, Raitakari OT, Ingelsson E, Järvelin MR, Thorsteinsdottir U, Franke L, Ikonen E, Kallioniemi O, Pietiäinen V, Lindgren CM, Stefansson K, Palotie A, McCarthy MI, Morris AP, Prokopenko I, Ripatti S; ENGAGE Consortium. Nat Genet. 2015 Jun;47(6):589-97. doi: 10.1038/ng.3300. Epub 2015 May 11.PMID: 25961943

9. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Kettunen J, Tukiainen T, Sarin AP, Ortega-Alonso A, Tikkanen E, Lyytikäinen LP, Kangas AJ, Soininen P, Würtz P, Silander K, Dick DM, Rose RJ, Savolainen MJ, Viikari J, Kähönen M, Lehtimäki T, Pietiläinen KH, Inouye M, McCarthy MI, Jula A, Eriksson J, Raitakari OT, Salomaa V, Kaprio J, Järvelin MR, Peltonen L, Perola M, Freimer NB, Ala-Korpela M, Palotie A, Ripatti S. Nature Genetics. 2012 Jan 29;44(3):269-76. doi: 10.1038/ng.1073.PMID: 22286219

10. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, Guiducci C, Perola M, Jula A, Sinisalo J, Lokki ML, Nieminen MS, Melander O, Salomaa V, Peltonen L, Kathiresan S. Lancet. 2010 Oct 23;376(9750):1393-400. doi: 10.1016/S0140-6736(10)61267-6.PMID: 20971364